Taizhou Overseas Pharmaceuticals Co., Ltd.

Primary objective: To compare the pharmacokinetic behavior of the test preparation, apixaban multi-release tablets (manufacturer: Taizhou Yueyang Pharmaceutical Development Co., Ltd.) and the comparative preparation, apixaban tablets (certificate holder: Qilu Pharmaceutical (Hainan) Co., Ltd.) in healthy Chinese subjects after oral administration under fasting state, using pharmacokinetic parameters as the primary endpoint evaluation index, and to evaluate the bioequivalence of the two preparations. Secondary objective: To observe the safety of the test preparation, apixaban multi-release tablets, and the comparative preparation, apixaban tablets in healthy Chinese subjects.

Main objective: To compare the efficacy of oral administration of the test preparation vildagliptin metformin sustained-release tablets (24h) (specification: 100mg/500mg) developed by Taizhou Yueyang Pharmaceutical Development Co., Ltd., vildagliptin tablets (trade name: Galvus®, specification: 50mg) of Novartis Europharm Ltd. as reference preparation 1, metformin hydrochloride sustained-release tablets (trade name: GLUCOPHAGE XR®, specification: 500mg) of Merck Serono Limited as reference preparation 2, and vildagliptin metformin tablets (trade name: EquMet®, specification: 50mg/250mg) marketed in Japan as reference preparation 3, respectively, in the postprandial state: 1 tablet of the test preparation vildagliptin metformin sustained-release tablets (24h) and 2 tablets of reference preparation 1 (1 tablet each in the morning and evening) + The blood concentration and main pharmacokinetic parameters of the reference preparation 2, 1 metformin hydrochloride sustained-release tablets, and the reference preparation 3, 1 vildagliptin metformin tablets in the morning and evening. Secondary objective: To evaluate the safety of the test preparation vildagliptin metformin sustained-release tablets (24h), the reference preparation 1 vildagliptin tablets + reference preparation 2 metformin hydrochloride sustained-release tablets, and the reference preparation 3 vildagliptin metformin tablets in the postprandial state in healthy Chinese subjects.

Primary objective: Using brivaracetam sustained-release tablets (specification: 100 mg) developed by Taizhou Yueyang Pharmaceutical Development Co., Ltd. as test preparation A (T1), brivaracetam sustained-release tablets (specification: 50 mg) as test preparation B (T2), and brivaracetam tablets (trade name: BRIVIACT®, specification: 50 mg) produced by UCB as reference preparation (R), to compare the plasma drug concentrations and main pharmacokinetic parameters between test preparation A (T1) and test preparation B (T2), test preparation A (T1) and reference preparation, and test preparation B (T2) and reference preparation, and to evaluate the relative bioavailability and sustained-release characteristics of the test preparations. Secondary objective: To evaluate the safety of test preparations A (T1), B (T2) brivaracetam sustained-release tablets and reference preparation (R) brivaracetam tablets after oral administration in Chinese healthy subjects under fasting state.